XML 62 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Schedule of Total Consideration of Business Acquisition (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Feb. 27, 2019
Consideration    
Contingent consideration $ 5,200  
Assets Acquired    
In-process research and development 173,240  
Myonexus Therapeutics, Inc. [Member]    
Consideration    
Purchase price 165,000 $ 8,800
Transactions costs and other fees 8,753  
Contingent consideration 4,500  
Total consideration 178,253  
Assets Acquired    
Cash and cash equivalents 1,197  
Prepaids 3,816  
In-process research and development 173,240  
Total assets acquired 178,253  
Liability Assumed    
Contingent consideration 4,500  
Total liability assumed $ 4,500